Piro Lito

Medical Oncology Fellow
Piro Lito

Lab Phone

My research is aimed at developing optimal therapies to treat cancers that harbor BRAF or KRAS mutations, as well as at understanding how these proteins affect intracellular signaling and cellular function.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Piro Lito discloses the following relationships and financial interests:

  • AmMax Bio, Inc.
    Provision of Services
  • Black Diamond Therapeutics, Inc.
    Provision of Services
  • Boehringer Ingelheim
    Provision of Services
  • Frontier Medicines Corporation
    Ownership / Equity Interests; Provision of Services
  • Repare Therapeutics
    Provision of Services (uncompensated)
  • Revolution Medicines
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures